A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties

AIDS Research and Human Retroviruses

Volumn 13, Issue 11, 1997, Pages 933-943

  Reimann, Keith A ^a,d   Lin, Wenyu ^a   Bixler, Sarah ^b   Browning, Beth ^b   Ehrenfels, Barbara N ^b   Lucci, Jodie ^b   Miatkowski, Konrad ^b   Olson, Dian ^b   Parish, Thomas H ^b   Rosa, Margaret D ^b   Oleson, Frederick B ^b   Hsu, Yen Ming ^b   Padlan, Eduardo A ^c   Letvin, Norman L ^a   Burkly, Linda C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BIOGEN   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; EXPRESSION VECTOR; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS INHIBITION;

EID: 0030788879     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.933     Document Type: Article

References (41)

1. Sattentau QJ and Weiss RA: The CD4 antigen: Physiological ligand and HIV receptor. Cell 1988;52:631-633.
2. Dalgleish AO, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4(T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984; 312:763-767.
3. Klatzman D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman J-C, and Montagnier L: T-lymphocytes T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 1984;312:767-768.
4. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, and Nicholson JKA: Binding of HTLV-III/LAV to T4+ Tcells by complex of the 110K viral protein and the T4 molecule. Science 1986;231:382-385.
5. Reimann KA, Burkly LC, Burrus B, Waite BCD, Lord CI, and Letvin NL: In vivo administration to thesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AID Res Hum Retroviruses 1993;9:199-207.
6. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, and Chisholm P: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol 1992;149:1779-1787.
7. Moore JP, Sattentau QJ, Klasse PJ, and Burkly LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J Virol 1992;66:4784-4793.
8. Orlandi R, Gussow DH, Jones PT, and Winter G: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-3837.
9. Kabat EA, Wu TT, Reid-Miller M, Perry HM, and Gottesman KS: Sequences of Proteins of Immunological Interest, Vol. 4, 5th Ed. U.S. Department of Health and Human Services, Bethesda, Maryland, 1991.
10. Klobeck HG, Bornkamm GW, Combriato G, Mocikat R, Pohlenz HD, and Zachau HG: Subgroup IV of human immunoglobulin κ light chains is encoded by a single germline gene. Nucleic Acids Res 1985;13:6515-6529.
11. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, and Borrebaeck CA: Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and polymerase chain reaction. Biochem Biophys Res Commun 1989; 160:1250-1256.
12. Padlan EA: Anatomy of the antibody molecule. Mol Immunol 1994;31:169-217.
13. Bebbington CR, Renner G, Thomson S, King D, Abrams D, and Yarranton GT: High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 1992;10:169-175.
14. Galfre G and Milstein C: Preparation of monoclonal antibodies: Strategies and procedures. Methods Enzymol 1981;73:3-46.
15. National Institutes of Health: Guide for the Care and Use of Laboratory Animals, Rev. Ed. Department of Health and Human Services Publication No. (NIH) 85-23. National Institutes of Health, Bethesda, Maryland, 1985.
16. Walker BD, Kowalski M, Goh WC, Kozarsky K, Krieger M, Rosen C, Rohrschneider L, Haseltine WA, and Sodroski J: Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA 1987; 84:8120-8124.
17. Reimann KA, Waite BCD, Lee-Parritz DE, Lin W, Uchanska-Ziegler B, O'Connell MJ, and Letvin NL: Use of human leukocyte-specific monoclonal antibodies for clinically immunophenotyping lymphocytes of rhesus monkeys. Cytometry 1994;17:102-108.
18. Cobbold SP, Rebello PRUB, Davies HFS, Friend PJ, and Clark MR: A simple method for measuring patient anti-globulin responses against isotopic or idiotypic determinants. J Immunol Methods 1990;127:19-24.
19. Norman DJ: Mechanisms of action and overview of OKT3. Ther Drug Monitoring 1995;17:615-620.
20. Shizuru JA, Alters SE, and Fathman CG: Anti-CD4 monoclonal antibodies in therapy: Creation of nonclassical tolerance in the adult. Immunol Rev 1992;129:105-130.
21. Riethmuller G, Rieber EP, Kiefersauer S, Prinz J, van der Lubbe P, Meiser B, Breedveld F, Eisenberg J, Kruger K, Deusch K, et al.: From antilymphocyte serum to therapeutic monoclonal antibodies: First experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 1992;129:81-104.
22. Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgarriff C, Sanders ME, and Koopman WJ: Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheumatism 1993;36:307-318.
23. Rose LM, Alvord EC, Hruby S, Jackevicius S, Petersen R, Warner N, and Clark EA: In vivo administration of anti-CD4 monoclonal antibody prolongs survival in longtailed macaques with experimental allergic encephalomyelitis. Clin Immunol Immunopathol 1987;45:405-423.
24. Jonker M, Goldstein G, and Balner H: Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations of the immune system in a rhesus monkey model. Transplantation 1983;35:521-526.
25. Cosimi AB, Burton RC, Kung PC, Colvin R, Goldstein G, Lifter J, Rhodes W, and Russell PS: Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplantation Proc 1981;13:499-503
26. Jonker M, Slingerland W, Treacy G, van Eerd P, Pak KY, Wilson E, Tam S, Bakker K, LoBuglio AF, Rieber P, et al.: In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees. Clin Exp Immunol 1993;93:301-307.
27. Delmonico FL, Cosimi AB, Kawai T, Cavender D, Lee W-H, Jolliffe LK, and Knowles RW: Nonhuman primate responses to murine and humanized OKT4A. Transplantation 1993;55:722-728.
28. Schneider WP, Glaser SM, Kondas JA, and Hakimi J: The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J Immunol 1993;150:3086-3090.
29. Stephens S, Emtage S, Vetterlein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, and Bodmer M: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995;85:668-674.
30. Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, and Colvin RB: Monoclonal antibody therapy: Anti-idiotypic and non-anti-idiotyic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986;41:572-578.
31. Lowder JN, Miller RA, Hoppe R, and Levy R: Suppression of antimouse immunoglobulin antibodies in subhuman primates receiving murine monoclonal antibodies against T cell antigens. J Immunol 1987;138:401-406.
32. Khazaeli MB, Conry RM, and LoBuglio AF: Human immune response to monoclonal antibodies. J Immunother 1994;15:42-52.
33. Pulito VL, Roberts VA, Adair JR, Rothermel AL, Collins AM, Varga SS, Martocello C, Bodmer M, Jolliffe LK, and Zivin RA: Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J Immunol 1996;156:2840-2850.
34. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FT, Davis J, Deeg HJ, Doneyu K, Martin PJ, Nash R, Storb R, and Strom TA: Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320-1327.
35. Letvin NL and King NW: Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 1990; 3:1023-1040.
36. Reimann KA, Cate RL, Wu Y, Palmer L, Olson D, Waite BCD, Letvin NL, and Burkly LC: In vivo administration of CD4-specific monoclonal antibody: Effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques. AIDS Res Hum Retroviruses 1995;11:517-525.
37. Attanasio R, Allan JS, and Kennedy RC: Monoclonal anti-CD4 as immunoprophylactic agents for human immunodeficiency virus infection. J Infect Dis 1993;168:515-516.
38. Rieber EP, Federle C, Reiter C, Krauss S, Gurtler L, Eberle J, Deinhardt F, and Riethmuller G: The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: An approach to postexposure prophylaxis. Proc Natl Acad Sci USA 1992; 89:10792-10796.
39. Dhiver C, Olive D, Rousseau S, Tamalet C, Lopez M, Galindo J-R, Mourens M, Hirn M, Gastaut J-A, and Mawas C: Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients. AIDS 1989;3:835-842.
40. Reiber EP, Reiter C, Gurtler L, Deinhardt F, and Riethmuller G: Monoclonal CD4 antibodies after accidental HIV infection. Lancet 1990;336:1007-1008.
41. Burkly L, Mulrey N, Blumenthal R, and Dimitrov DS: Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol 1995; 69:4267-4273.